The management of patients with metastatic prostate cancer during the COVID-19 pandemic

References

• 1. del Rio C, Malani PN. COVID-19 – new insights on a rapidly changing epidemic. JAMA 323(14), 1339–40 (2020).
  Medline CASGoogle Scholar
• 2. WHO. Coronavirus disease 2019 (COVID-19) situation report – 101. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-101-covid-19.pdf?sfvrsn=d1c3e800_2
  Google Scholar
• 3. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18), 1775–1776 (2020).
  Medline CASGoogle Scholar
• 4. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 395(10231), 1225–28 (2020).
  Medline CASGoogle Scholar
• 5. Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 5(2), e000765 (2020).
  MedlineGoogle Scholar
• 6. Burki TK. Cancer guidelines during the COVID-19 pandemic. The Lancet Oncology 21(5), 629–30 (2020).
  Medline CASGoogle Scholar
• 7. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat. Rev. Clin. Oncol. 17(5), 268–270 (2020).
  Medline CASGoogle Scholar
• 8. Akladios C, Azais H, Ballester M et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic-FRANCOGYN group for the CNGOF. J. Gynecol. Obstet. Hum. Reprod. doi: 10.1016/j.jogoh.2020.101729 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 9. Bitar N, Kattan J, Kourie HR, Mukherji D, Saghir NE. The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. Future Oncol. 16(11), 615–617 (2020).
  CASGoogle Scholar
• 10. van de Haar J, Hoes LR, Coles CE et al. Caring for patients with cancer in the COVID-19 era. Nat. Med. 1–7 (2020).
  MedlineGoogle Scholar
• 11. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271–280 (2020).
  Medline CASGoogle Scholar
• 12. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31), 4596–4599 (2007).
  Medline CASGoogle Scholar
• 13. Yu J, Yu J, Mani R-S et al. An integrated network of androgen receptor, polycomb and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17(5), 443–454 (2010).
  Medline CASGoogle Scholar
• 14. Rassy E, Khoury-Abboud RM, Ibrahim N et al. What the oncologist needs to know about COVID-19 infection in cancer patients. doi:10.2217/fon-2020-0312 (2020) (Epub ahead of print).
  Google Scholar
• 15. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21(3), 335–337 (2020).
  Medline CASGoogle Scholar
• 16. Zhang H-Y, Wang L-W, Chen Y-Y et al. A multicentre study of 2019 novel coronavirus disease outcomes of cancer patients in Wuhan, China. medRxiv doi: 2020.03.21.20037127 (2020) (Epub ahead of print).
  Google Scholar
• 17. Guan W, Ni Z, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382(18), 1708–20 (2020).
  Medline CASGoogle Scholar
• 18. Zhang L, Zhu F, Xie L et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. doi: 10.1016/j.annonc.2020.03.296 (2020) (Epub ahead of print).
  Google Scholar
• 19. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 20. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49), 5501–5511 (2013).
  Medline CASGoogle Scholar
• 21. Mohler JL, Antonarakis ES, Armstrong AJ et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17(5), 479–505 (2019).
  Medline CASGoogle Scholar
• 22. Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13–24 (2019).
  Medline CASGoogle Scholar
• 23. Fizazi K, Shore N, Tammela TL et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380(13), 1235–1246 (2019).
  Medline CASGoogle Scholar
• 24. Sweeney C, Chen YH, Liu G et al. Longterm efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann. Oncol. 27, 243–265 (2016).
  Google Scholar
• 25. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017).
  Medline CASGoogle Scholar
• 26. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
  Medline CASGoogle Scholar
• 27. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, Phase III trial. Lancet Oncol. 14(2), 149–158 (2013).
  Medline CASGoogle Scholar
• 28. Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
  Medline CASGoogle Scholar
• 29. Aoun F, El Rassy E, Sleilaty G, Assi T, Bakouny Z, Kattan J. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel? Future Oncol. 13(30), 2785–2790 (2017).
  CASGoogle Scholar
• 30. Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled Phase III trial. Lancet 392(10162), 2353–2366 (2018).
  MedlineGoogle Scholar
• 31. Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, Phase III trial. Lancet Oncol. 20(5), 686–700 (2019).
  Medline CASGoogle Scholar
• 32. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
  Medline CASGoogle Scholar
• 33. Duga S, Asselta R, Lazzeri M et al. Impact of anti-androgenic therapies on COVID-19: an observational study in male population from a COVID-19 regional centre of Lombardy (Italy). medRxiv doi: 10.1101/2020.04.20.20068056 (2020) (Epub ahead of print).
  Google Scholar
• 34. Sydes MR, Spears MR, Mason MD et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29(5), 1235–1248 (2018).
  Medline CASGoogle Scholar
• 35. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94(7), e00127–20 (2020).
  MedlineGoogle Scholar
• 36. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol. Res. 125, 21–38 (2017).
  Medline CASGoogle Scholar
• 37. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
  Medline CASGoogle Scholar
• 38. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).
  Medline CASGoogle Scholar
• 39. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242–245 (2008).
  Medline CASGoogle Scholar
• 40. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010).
  Medline CASGoogle Scholar
• 41. Eisenberger M, Hardy-Bessard A-C, Kim CS et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m²) and the currently approved dose (25 mg/m²) in postdocetaxel patients with metastatic castration-resistant prostate cancer – PROSELICA. J. Clin. Oncol. 35(28), 3198–3206 (2017).
  Medline CASGoogle Scholar
• 42. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase III study. Lancet Oncol. 16(2), 152–160 (2015).
  Medline CASGoogle Scholar
• 43. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase III study. Lancet Oncol. 13(10), 983–992 (2012).
  Medline CASGoogle Scholar
• 44. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424–433 (2014).
  MedlineGoogle Scholar
• 45. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
  Medline CASGoogle Scholar
• 46. de Wit R, de Bono J, Sternberg CN et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381(26), 2506–2518 (2019).
  Medline CASGoogle Scholar
• 47. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43(3), 408–410 (1994).
  Medline CASGoogle Scholar
• 48. Akaza H, Hinotsu S, Usami M et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a Phase III, double-blind, randomized study for survival. Cancer 115(15), 3437–3445 (2009).
  Medline CASGoogle Scholar
• 49. Khan MM. Immunosuppressive agents. In: Immunopharmacology. Springer, NY, USA, 131–156 (2016).
  Google Scholar
• 50. Kourie HR, Antoun J, El Rassy E, Rassy M, Sader-Ghorra C, Kattan J. Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: a literature review. J. Bone Oncol. 4(3), 77–79 (2015).
  MedlineGoogle Scholar
• 51. EMA. Guidance sponsors how to manage clinical trials during COVID-19 pandemic. (2020). www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemic
  Google Scholar
• 52. US FDA. FDA guidance on conduct of clinical trials of medical products during COVID-19 public health. Emergency Guidance for industry, investigators, and institutional review boards. (2020). www.fda.gov/media/136238/download
  Google Scholar
• 53. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3), 269–271 (2020).
  Medline CASGoogle Scholar
• 54. Gautret P, Lagier J-C, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/
  MedlineGoogle Scholar